logo-loader
viewValiRx PLC

ValiRx eyes international partnerships

globalpolitics350.jpg

Cancer-focused life science company ValiRx (LON:VAL) has accepted an invitation to participate in a visit to the 2015 BIO International Convention in Philadelphia,

The Market Visit has been organised by the Mayor of London's Export Programme, in partnership with UK Trade & Investment (UKTI), to offer London's small-to-medium sized enterprises (SMEs) an opportunity to attend this major industry international event where they will get a chance to mingle with representatives of the world's leading pharmaceutical and biotechnology companies.

Last year's convention featured more than 1,800 exhibitors and 55 state, regional and country pavilions in an area of over 160,000 square feet. The convention was visited by attendees from leading biotech companies, top 25 pharma companies and more than 300 academic institutions, including research labs and government agencies, ValiRx reported.

Furthermore, according to the 2013 Campbell Alliance's “Deal Makers' Intentions” report, the majority of successful deals in the biopharma industry are a result of participating in these sorts of partnering events.

"I am delighted ValiRx has been invited to join an impressive British delegation of biotech businesses attending this major industry event,” said Dr Satu Vainikka, chief executive officer of ValiRx.  

“I look forward to the company building its profile on the international stage, particularly following our successful poster presentation at the recent American Association for Cancer Research (AACR) conference in Philadelphia and I look forward to ValiRx expanding its network of relationships to the benefit of our shareholders," he added. 

Shares in ValiRx were up 2.4% in late morning trading.

Quick facts: ValiRx PLC

Price: 0.0425 GBX

AIM:VAL
Market: AIM
Market Cap: £5.22 k
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ValiRx PLC named herein, including the promotion by the Company of ValiRx PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: Green light for ValiRx to increase dose of VAL201

Top stories from the Proactive Investors UK newsroom. ValirX (LON:VAL) has received a boost for its prostate cancer treatment VAL201 after UK regulators approved a substantial increase in the doses allowed in future clinical trials. The phase I/II trial so far has met all primary and...

on 20/6/19

2 min read